Andon Health Co.Ltd(002432) again trapped in the vortex of public opinion.
On March 1, Andon Health Co.Ltd(002432) intraday share price was close to the limit, closing down 9.48%.
The fuse was quickly identified: some investors raised questions on the interactive platform about whether the company’s ihealth products were cancelled by the U.S. Food and drug administration due to their low sensitivity.
Further inquiry found that the news came from a teleconference organized by Zheshang Securities Co.Ltd(601878) organization.
According to the minutes and recordings of the meeting posted on the Internet, an expert suspected to represent Hangzhou Biotest Biotech Co.Ltd(688767) said, “we have also learned that the U.S. EUA certificate of Andon Health Co.Ltd(002432) products will be cancelled, and we have been interviewed by the Securities Regulatory Commission. The feedback effect of Andon Health Co.Ltd(002432) products in the U.S. market is not good, mainly due to the problem of product sensitivity” ” Andon Health Co.Ltd(002432) will have such a problem because its products are not updated and iterated. At present, the detection rate is only 60% – 70%”…
And just one day before the call, Andon Health Co.Ltd(002432) just published an article on its official account. “Ihealth covid-19 test kit has performed well in the independent evaluation of Harvard Medical School. It is also a covid-19 antigen test kit that realizes single on-site detection and provides reliable test results in 15 minutes without any additional instruments and equipment. Ihealth made in China is not inferior to overseas brands at all, and has received a very positive evaluation in this experiment.”
in this regard, the reporter of Shanghai Securities News interviewed the person in charge of Andon Health Co.Ltd(002432) relevant departments. According to the person in charge, the company learned that the above teleconference was hosted by Zheshang Securities Co.Ltd(601878) , Shanghai bangtuo Technology Co., Ltd. The company is in the process of producing and selling the “vic-19” antigen kit and “OTC kit” in accordance with the contract. At present, the company has no such situation. The above rumors are false statements without any basis. The company has asked the above two companies and the expert Wu to immediately stop the infringement, clarify the facts and make a public apology for the misleading information, and ensure that similar events will not occur in the future
Andon Health Co.Ltd(002432) the person in charge also said that the company has entrusted Guohao law firm (Tianjin) to send a lawyer’s letter to Zheshang Securities Co.Ltd(601878) and Shanghai bangtuo Technology Co., Ltd. on the above matters. If the above matters have adverse consequences for listed companies and capital markets, the company will investigate their responsibilities through legal means
On March 1, Hangzhou Biotest Biotech Co.Ltd(688767) in response to the media interview, said that the experts participating in Zheshang Securities Co.Ltd(601878) teleconference were not the company’s personnel; The company has communicated with Zheshang Securities Co.Ltd(601878) and Zheshang Securities Co.Ltd(601878) is verifying the participants Hangzhou Biotest Biotech Co.Ltd(688767) did not participate in the conference call, which has nothing to do with the matter.
Later, Zheshang Securities Co.Ltd(601878) responded to the media that after verification, the Agency organized an expert exchange telephone conference with the theme of “covid-19 antigen detection industry analysis” on February 27, and invited experts with relevant industry background. The telephone conference is only closed to the customers of the agency’s contracting institutions. Among them, in the question exchange session after the telephone meeting, the expert mentioned ” Andon Health Co.Ltd(002432) ” when discussing professional issues.
The relevant person in charge of Zheshang Securities Co.Ltd(601878) Research Institute said that the relevant comments made by the experts only involve professional discussion, and their views and comments come from the personal understanding of the experts themselves; The information or opinions expressed by experts in the teleconference belong to their personal views and do not represent the research views of Zheshang Securities Co.Ltd(601878) Research Institute. Without Zheshang Securities Co.Ltd(601878) authorization, no one has the right to disclose any information related to the telephone, including but not limited to text, video and audio.
In the stock bar, some investors believe that “we must give investors an explanation”.
Some investors also said they would be held accountable for the relevant securities companies.
Lawyer Wang Zhibin of Shanghai Minglun law firm introduced in an interview with the reporter of Shanghai Securities Daily, “Article 56 of the securities law stipulates that Whoever fabricates or disseminates false or misleading information, disturbs the securities market and causes losses to investors shall be liable for compensation according to law. This article emphasizes that the perpetrator has subjective malice. Generally speaking, no matter whether the views expressed by industry experts are correct or not, it shall not be regarded as’ fabricating ‘false information. However, if there is a clear If the chain of evidence can prove that the expert intentionally publishes his statement and intentionally affects the stock price, this clause can be applied. At this time, the damaged investor has the right to file a claim lawsuit, and the listed company can also file an infringement lawsuit for its loss. “
In response to the above incident, lawyer Yang Zhaoquan, director of Beijing Weinuo law firm and distinguished member of the legislative Advisory Committee of the Standing Committee of the Beijing Municipal People’s Congress, told the reporter of Shanghai Securities News, “At a closed meeting without the participation of ordinary investors, every expert has the right to express his own views. Although these views may not be consistent with the facts, they should not bear legal responsibility as long as they are not deliberately fabricated. If the expert’s speech is leaked out and the investors buy and sell stocks as’ inside information ‘, the investors are responsible for their trading results, and the expert who speaks does not agree assumed liabilities. If the person who divulges the information without authorization does not tamper with the content and source of the information to mislead others, he has no legal responsibility and will only bear moral responsibility for violating the rules of the venue. “
therefore, Yang Zhaoquan specially reminds investors to treat information from various channels objectively and rationally. Don’t blindly believe in personal views and expert opinions. The so-called “gossip” and “inside information” should be treated with caution and should not blindly follow suit
